Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiolabeled iododeoxyuridine: safety evaluation

K A Harrison1, G V Dalrymple, J Baranowska-Kortylewicz

  • 1Department of Radiology, University of Nebraska Medical Center, Omaha 68198-1045, USA.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|April 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The social, behavioral, and health effects of phencyclidine (PCP) use.

Journal of youth and adolescence·2013
Same author

Tumor suppressor functions of Dnmt3a and Dnmt3b in the prevention of malignant mouse lymphopoiesis.

Leukemia·2013
Same author

Serum and hair selenium levels in hereditary nonpolyposis colorectal cancer.

Biological trace element research·2013
Same author

The effect of selenium on cell proliferation in liver and colon.

Biological trace element research·2013
Same author

In vitro regulation of human lymphocyte proliferation by selenium.

Biological trace element research·2013
Same author

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.

British journal of cancer·2013

Radiolabeled iododeoxyuridine (IUdR) shows promise as a therapeutic agent. Studies in pigs and humans indicate minimal adverse effects on normal tissues, suggesting its safety for therapeutic use.

Area of Science:

  • Oncology
  • Radiochemistry
  • Pharmacology

Background:

  • Radiolabeled iododeoxyuridine (IUdR) is being investigated for therapeutic potential.
  • Previous research focused on assessing IUdR's safety and identifying adverse effects on normal tissues.
  • The liver rapidly dehalogenates IUdR, making intravenous administration less effective.

Purpose of the Study:

  • To evaluate the safety of radiolabeled iododeoxyuridine (IUdR) as a potential therapeutic agent.
  • To assess adverse effects on normal tissues in preclinical (pigs) and clinical (human) studies.
  • To explore alternative administration routes, specifically intra-arterial and intravesicular, due to rapid dehalogenation via the intravenous route.

Main Methods:

  • Preclinical studies in farm pigs involved multiple administrations of [125I]IUdR into the aorta, carotid artery, and bladder.

Related Experiment Videos

  • Pharmacokinetic and metabolite analyses were conducted using venous blood samples.
  • Histologic examination of tissues and autoradiography were performed.
  • Clinical studies in human patients with liver metastases and bladder carcinoma utilized intra-arterial and intravesicular administration of [123I]IUdR and [125I]IUdR.

    • Main Results:

    • No adverse effects on normal tissues were observed in pigs or humans.
    • Hematologic and metabolic indices remained unaltered in study subjects.
    • Intravesicular administration demonstrated minimal leakage of IUdR into the systemic circulation.

    Conclusions:

    • Radiolabeled iododeoxyuridine (IUdR) demonstrates a favorable safety profile for therapeutic applications.
    • Intra-arterial and intravesicular administration routes appear safe, with minimal impact on normal tissues.
    • IUdR is a promising candidate for targeted cancer therapies with low systemic toxicity.